-
Anti-obesity Drugs market is estimated to grow at a CAGR of 21.2% by 2034: Visiongain
12 Apr 2024 15:17 GMT
… complications, including type 2 diabetes, cardiovascular diseases, and psychological issues such … . Competitive Landscape Key players include, Arena Pharmaceuticals Ltd., Bayer AG, Boehringer Ingelheim …
-
Zura Bio Names Robert Lisicki as CEO & Director of the Board
08 Apr 2024 14:29 GMT
… the Chief Commercial Officer at Arena Pharmaceuticals from October 2018 to March … General Manager of Inflammation and Cardiovascular at Regeneron Pharmaceuticals. In this …
-
Zura Bio Announces Robert Lisicki as CEO and Director
08 Apr 2024 10:26 GMT
… the Chief Commercial Officer at Arena Pharmaceuticals from October 2018 to March … General Manager of Inflammation and Cardiovascular at Regeneron Pharmaceuticals. In this …
-
Global Pulmonary Arterial Hypertension (PAH) Drugs Market Report 2022 to 2027: Key Players Include Arena Pharmaceuticals, AstraZeneca, Bayer Aktiengesellschaft and Daiichi Sankyo - ResearchAndMarkets.com
03 Feb 2023 10:55 GMT
… Pharmaceuticals Ltd (Johnson & Johnson)
Arena Pharmaceuticals Inc.
AstraZeneca PLC
Bayer Aktiengesellschaft … administered.
The increasing prevalence of cardiovascular and pulmonary disorders is one …
-
Opportunity and New Therapies Are Driving Interest in a Rare Cardiovascular D...
07 Aug 2023 06:01 GMT
… Therapeutics, which in 2018 paid Arena Pharmaceuticals a potential $1.2 billion … Patel, a healthcare analyst in cardiovascular and metabolic disorders at GlobalData … global clinical development at Merck Cardiovascular, this anti-proliferation approach means …
-
Pfizer Completes Acquisition of Arena Pharmaceuticals
12 Mar 2022 06:52 GMT
… completion of its acquisition of Arena Pharmaceuticals, a clinical stage company … several immuno-inflammatory diseases.
Arena Pharmaceuticals brings to Pfizer a portfolio … also includes two development-stage cardiovascular assets: temanogrel for microvascular …
-
Pfizer Completes Acquisition of Arena Pharmaceuticals
11 Mar 2022 13:34 GMT
… completion of its acquisition of Arena Pharmaceuticals, a clinical stage company … several immuno-inflammatory diseases.
Arena Pharmaceuticals brings to Pfizer a portfolio … also includes two development-stage cardiovascular assets: temanogrel for microvascular …
-
Bristol Myers Squibb's versatile Zeposia doesn't make the grade in Crohn's disease trial
29 Mar 2024 17:25 GMT
… .D., BMS’ head of immunology, cardiovascular and neuroscience development, said in … $6.7 billion acquisition of Arena Pharmaceuticals. Velsipity also is being investigated …
-
Pfizer to buy Arena Pharmaceuticals in $6.7 billion deal
16 Dec 2021 08:00 GMT
… inked a deal to buy Arena Pharmaceuticals in an all-cash deal … pipeline includes two earlier-stage cardiovascular treatments. The first, temanogrel, is …
-
Pfizer to Acquire Arena Pharmaceuticals
13 Dec 2021 11:45 GMT
Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced … pipeline includes two development-stage cardiovascular assets, temanogrel and APD418. Temanogrel … at least 90 days.
About Arena Pharmaceuticals
ARENA is a team with …